Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Cryoport Reports 56% Revenue Growth for Fiscal Year Ended December 31, 2017

Cryoport added 85 new biopharma trials in 2017

Cryoport now supports a total of 214 trials with 26 Phase III clinical trials

Cryoport, Inc.

News provided by

Cryoport, Inc.

Mar 06, 2018, 04:10 ET

Share this article

Share toX

Share this article

Share toX

IRVINE, Calif., March 6, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the global leader in temperature-controlled logistics dedicated to the life sciences industry, today announced financial results for the three and twelve-month periods ended December 31, 2017.

Jerrell Shelton, Chief Executive Officer of Cryoport, commented, "2017 was an inflection point for our Company, as strong momentum in the biopharma market drove a year-over-year total revenue growth of 56%. We improved systems, added 'strength to our bench' of personnel and entered into long-term commercial logistics agreements supporting Gilead's Kite Pharma (YescartaTM) and Novartis (KymriahTM), the first FDA-approved CAR-T therapies to be commercialized. We believe our agreements supporting these first-to-market, high-profile and ground-breaking immunotherapies further cement our market leading position and reputation in the global biopharma market. As Kymriah™ and Yescarta™ are ramped to full commercialization, they are expected to drive significant revenue growth for Cryoport as commercial demand for these therapies is answered and accelerates.

"Cryoport's biopharma revenue increased 63%, contributing 76% of total revenue, for the fourth quarter of 2017, compared to the same period in 2016, with clinical and early stage commercial programs providing the primary catalysts for our rapid expansion. In 2017, we reported a net increase of 85 clinical trials that we support as many of the industry's leading and most innovative biopharma companies have integrated our unrivalled cold-chain logistics solutions into their collection and distribution processes and consider Cryoport's logistics solutions to be essential to their cell-based regenerative immunotherapies such as CAR T-cell therapies and other regenerative therapies such as allogenic stem cell therapies. 

"The regenerative medicine market continues to generate increased investment, with $7.5 billion raised in 2017, compared with $4.2 Billion in 2016, according to The Alliance for Regenerative Medicine (ARM) located in Washington, DC.  Furthermore, we anticipate the potential of an additional 5-7 Cryoport supported new BLA/EMA filings in the next 12 months, increasing from our previous estimate of 2-4.  We, therefore, expect Cryoport's position as the logistical backbone of the regenerative medicine industry to strengthen, accelerate and grow in both the near and long-term.

"Our technologically advanced logistics solutions and first-in-class reputation across the life sciences industry also drove new client agreements and improved revenue growth in our animal health and reproductive medicine markets throughout the year. In the fourth quarter of 2017, our 62% revenue growth in the animal health market compared to the same period in 2016 was primarily driven by a new client headquartered in Germany. In reproductive medicine, our United States market remains robust and, as a matter of priority, for the present, we continue to direct our sales and marketing efforts for our CryostorkSM solutions toward U.S. clients. Both animal health and reproductive medicine are consistent and growing sources of revenue and we plan to continue to expand our footprint in these markets throughout 2018," concluded Mr. Shelton.

Market Highlights:

Biopharma

  • Biopharma revenue increased by 72% in the twelve months ended December 31, 2017 compared to the same period in 2016; for the quarter ended December 31, 2017, biopharma revenue increased 63% compared to the same period in 2016.
  • 85 new biopharma trials were added in the twelve-months ended December 31, 2017, and 19 new biopharma trials in the fourth quarter of 2017.
  • Cryoport is supporting a net total of 214 clinical trials, of which 26 are in Phase III, compared with 129 as of December 31, 2016, 18 of which were in Phase III.
  • Novartis signed a long-term commercial agreement with Cryoport for Kymriah™ in June 2017 to support the commercial launch of its FDA-approved CAR-T therapy.
  • Gilead's Kite Pharma signed a long-term commercial agreement with Cryoport for Yescarta™ in August 2017 to support the commercial launch of its FDA-approved CAR-T therapy.
  • Subsequent to the year end, Cryoport announced a collaboration with McKesson Specialty Health, a division of McKesson Corporation, designed to bolster logistics services to support delivery of cell and gene therapies to patients at points of care.
  • Commenced construction of two new Cryoport Global Logistics Centres, one located in the Eastern United States and the other in Amsterdam, both with scheduled openings during the first half of 2018.

Animal Health

  • Revenue from the animal health market was up 34% for the twelve months ended December 31, 2017 compared to the same period in 2016, driven by cell bank moves for a new client and an increase in volume from existing clients.
  • Animal health revenue for the three-month period ended December 31, 2017 was up 62% compared to the same period in 2016, primarily driven by a new client headquartered in Germany.

Reproductive Medicine

  • Reproductive medicine revenue increased by 11% for the twelve months ended December 31, 2017 compared to the same period in 2016; for the quarter ended December 31, 2017, overall reproductive medicine revenue decreased 3% compared to the same quarter in 2016.
  • Launched MyCryostork.com website to focus on the needs of intended parents and to begin to build global brand awareness.

Financial Results:

  • Revenue increased 56% to $12.0 million for the twelve-month period ended December 31, 2017 compared to the same period in 2016. This growth was driven by an overall increase in the number of clients utilizing the Company's solutions complemented by growth and frequency of shipments from current clients.
  • Revenue increased 49% to $3.3 million for the three-month period ended December 31, 2017 compared to the same period in 2016. This growth was driven by an overall increase in the number of clients utilizing the Company's solutions complemented by growth and frequency of shipments from current clients.
  • Gross margin for the twelve and three months ended December 31, 2017 was 50% and 52%, respectively, compared to 40% and 42% for the twelve and three-month periods in the prior year, respectively. Gross margin improvements were driven by increased business volume, annual pricing adjustments and the positive impact of economies of scale.
  • As a result of investments in the build out of infrastructure for the future during FY 2017, which includes adding new competencies and services, operating costs and expenses increased by $2.0 million and $1.0 million for fiscal year ended and the three months ended December 31, 2017, respectively.
  • Net losses for the twelve and three-month periods ended December 31, 2017 were $7.9 million and $2.3 million, respectively, which reflected improvements of 40% and 47% compared to net losses of $13.1 million and $4.3 million for the same twelve and three-month periods in the prior year. Net loss attributable to common stockholders for the twelve and three-month periods ended December 31, 2017 was $7.9 million, or $0.34 per share and $2.3 million, or $0.09 per share, respectively, compared with $13.2 million, or $0.93 per share, and $4.3 million, or $0.25 per share, for the same twelve and three-month periods in the prior year.
  • Adjusted EBITDA for the twelve and three-month periods ended December 31, 2017 was ($3.7 million) and ($1.1 million), respectively, compared with ($5.3 million) and ($1.1 million) for the same twelve and three-month periods in the prior year.
  • The Company has no debt and reported $15.0 million in cash and cash equivalents as of December 31, 2017, compared to $4.5 million as of December 31, 2016. The increase in cash and cash equivalents includes net proceeds of $11.4 million received from an underwritten public offering on March 31, 2017 and net proceeds of $5.2 million from the exercise of warrants and stock options during the twelve-month period ended December 31, 2017.
  • Subsequent to year end, the Company completed a warrant tender offer resulting in gross proceeds of $4.7 million.

Further information on Cryoport's financial results is included on the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport's financial performance is provided in Cryoport's annual report on Form 10-K for the twelve and three-month periods ended December 31, 2017, which will be filed with the Securities and Exchange Commission ("SEC") on March 8, 2018. The full report will be available on the SEC Filings section of the Investor Relations section of the Company's website at www.cryoport.com.

Earnings Conference Call Information

Date:

Tuesday, March 6, 2018

Time:

4:30 p.m. EST

Dial-in numbers:

+1 (877) 407-9716 (U.S.) or +1 (201) 493-6779 (International)  

Confirmation code:

Request "Cryoport Call"

Live webcast:

'Investor Relations' section at www.cryoport.com or at this link. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

An archive of the webcast will be available approximately three hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.cryoport.com for a limited time. To access the replay of the webcast, please follow this link. A dial-in replay of the call will also be available to those interested until March 13, 2018.  To access the replay, dial 1 (844) 512-2921 (United States) or 1 (412) 317-6671 (International) and enter replay pin number: 13676420.

About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

Cryoport is dedicated to:

  • simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;
  • delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and
  • providing vital information that provides peace of mind throughout the life of each logistics process.

For more information, visit www.cryoport.com. Sign up to follow @cryoport on Twitter at www.twitter.com/cryoport.

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Company's 10-K for the year ended December 31, 2017 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport Inc. and Subsidiaries






 Condensed Consolidated Statements of Operations















 Three Months Ended
December 31, 


 Years Ended
December 31, 


 Nine Months Ended
December 31, 




2017


2016


2017


2016


2016




(unaudited)


(unaudited)




(unaudited)



Revenues


$      3,322,000


$      2,228,879


$  11,954,267


$      7,678,816


$      6,123,271

Cost of revenues

1,608,750


1,288,048


5,987,834


4,577,393


3,603,655

Gross margin

1,713,250


940,831


5,966,433


3,101,423


2,519,616













Operating costs and expenses:











General and administrative

2,031,446


1,697,373


7,420,837


6,449,196


4,634,775


Sales and marketing

1,572,664


1,142,213


5,232,406


4,820,230


3,573,204


Research and development

380,315


103,149


1,205,692


598,106


453,628

Total operating costs and expenses

3,984,425


2,942,735


13,858,935


11,867,532


8,661,607













Loss from operations

(2,271,175)


(2,001,904)


(7,892,502)


(8,766,109)


(6,141,991)

Other (expense) income:











Interest expense

-


(17,675)


(15,693)


(139,416)


(58,222)


Warrant repricing expense

-


(2,265,434)


-


(4,195,252)


(4,195,252)


Other income (expense), net

2,418


1,470


14,337


(6,770)


(1,898)

Loss before provision for income taxes

(2,268,757)


(4,283,543)


(7,893,858)


(13,107,547)


(10,397,363)

Provision for income taxes

(912)


(311)


(5,143)


(5,673)


(5,673)

Net loss


(2,269,669)


(4,283,854)


(7,899,001)


(13,113,220)


(10,403,036)

Preferred stock beneficial conversion charge

-


-


-


-


-

Undeclared cumulative preferred dividends

-


-


-


(75,460)


-

Net loss attributable to common stockholders

$   (2,269,669)


$   (4,283,854)


$  (7,899,001)


$ (13,188,680)


$ (10,403,036)













Net loss per share attributable to common stockholders - basic and diluted

$              (0.09)


$              (0.25)


$            (0.34)


$              (0.93)


$              (0.68)

Weighted average shares outstanding - basic and diluted

25,545,645


16,847,011


22,963,382


14,220,977


15,393,402

Cryoport Inc. and Subsidiaries

Condensed Consolidated Balance Sheets





December 31,


December 31,




2017


2016







Current Assets:





Cash and cash equivalents

$   15,042,189


$      4,524,529


Accounts receivable, net

1,625,476


1,195,479


Inventories

114,796


89,499


Prepaid expenses and other current assets

516,427


286,919



Total current assets

17,298,888


6,096,426

Property and equipment, net

2,511,174


1,647,104

Intangible assets, net

90,646


5,000

Deposits


363,403


363,403



Total assets

$   20,264,111


$      8,111,933







Current liabilities:





Accounts payable and other accrued expenses

$      1,259,629


$      1,160,299


Accrued compensation and related expenses

925,514


419,034


Related party notes payable and accrued interest, net of discount

-


651,934



Total current liabilities

2,185,143


2,231,267


Deferred rent liability

192,202


200,264



Total liabilities

2,377,345


2,431,531



Total stockholders' equity 

17,886,766


5,680,402



     Total liabilities and stockholders' equity 

$   20,264,111


$      8,111,933

Note Regarding Use of Non-GAAP Financial Measures
This news release contains non-GAAP financial measures as defined in Regulation G of the Securities Exchange Act of 1934.  These financial measures are not calculated in accordance with generally accepted accounting principles (GAAP) and are not based on any comprehensive set of accounting rules or principles. In evaluating the Company's performance, management uses certain non-GAAP financial measures to supplement financial statements prepared under GAAP. Management believes the following non-GAAP financial measure, adjusted EBITDA, to provide a useful measure of the Company's operating results, a meaningful comparison with historical results and with the results of other companies, and insight into the Company's ongoing operating performance. Further, management and the Board of Directors utilize these non-GAAP financial measures to gain a better understanding of the Company's comparative operating performance from period-to-period and as a basis for planning and forecasting future periods. Management believes these non-GAAP financial measures, when read in conjunction with the Company's GAAP financials, are useful to investors because they provide a basis for meaningful period-to-period comparisons of the Company's ongoing operating results, including results of operations, against investor and analyst financial models, identifying trends in the Company's underlying business and performing related trend analyses, and they provide a better understanding of how management plans and measures the Company's underlying business.

Cryoport Inc. and Subsidiaries






Adjusted EBITDA Reconciliation






(unaudited)















 Three Months Ended
December 31, 


Years Ended
December 31,


Nine Months Ended
December 31,




2017


2016


2017


2016


2016

GAAP net loss 


$ (2,269,669)


$ (4,283,854)


$ (7,899,001)


$ (13,113,220)


$ (10,403,036)


Non-GAAP adjustments to net loss:












Depreciation and amortization expense

172,851


102,681


664,831


374,202


301,297



Interest expense

-


17,675


15,693


139,416


58,222



Stock-based compensation expense

1,017,923


780,010


3,547,781


3,117,946


2,329,003



Warrant repricing expense

-


2,265,434


-


4,195,252


4,195,252



Income taxes

(912)


311


5,143


5,673


5,673

Adjusted EBITDA


$ (1,079,807)


$ (1,117,743)


$ (3,665,553)


$    (5,280,731)


$    (3,513,589)

SOURCE Cryoport, Inc.

Related Links

https://www.cryoport.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

MVE Biological Solutions, A Cryoport Company, Introduces Real-Time Integrated Condition Monitoring Systems For Cryogenic Dewars

MVE Biological Solutions, A Cryoport Company, Introduces Real-Time Integrated Condition Monitoring Systems For Cryogenic Dewars

Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences, today announced the unveiling of MVE Biological...

Cryoport Systems Expands Global Footprint with New Global Supply Chain Center in Paris, France

Cryoport Systems Expands Global Footprint with New Global Supply Chain Center in Paris, France

Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Earnings

Earnings

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.